Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tango Therapeutics

Request full access

Biotechnology company developing novel medicines

Boston, United StatesFounded 2017Biotech & Life Sciences

About Tango Therapeutics

Tango Therapeutics is a biotechnology startup focused on developing innovative cancer treatments. The company leverages the principle of synthetic lethality, a concept where two genes interact in a way that the loss of both leads to cell death, but the loss of just one does not. This approach allows Tango to create medicines that specifically target and kill cancer cells while sparing healthy ones.

Tango Therapeutics operates in the oncology market, which involves the study and treatment of tumors. Their primary clients are healthcare providers, including hospitals and specialized cancer treatment centers, as well as pharmaceutical companies looking for cutting-edge cancer therapies.

The business model of Tango Therapeutics revolves around research and development (R&D) of new cancer drugs. They collaborate with larger pharmaceutical companies, such as Gilead Sciences, to co-develop these therapies. This collaboration not only provides financial support but also accelerates the development and commercialization of their treatments. Tango Therapeutics generates revenue through these partnerships, as well as through funding rounds, such as their recent $60 million Series B financing.

Tango's robust pipeline of therapies is backed by a passionate team and bold leadership, including notable appointments like Reid Huber, PhD, and Malte Peters, MD, to their Board of Directors. These strategic moves strengthen their executive team and enhance their capability to bring next-generation targeted immunotherapies to market.

In summary, Tango Therapeutics is a pioneering biotech firm dedicated to creating genetically targeted cancer treatments through strategic collaborations and a strong focus on R&D.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2021

Tango Therapeutics in the Boston ecosystem

Live from Dealroom

The Tango Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

30 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later25 investors entered at this stage

Employees mapped 161 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 21 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$4M

18 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Tango Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.